Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?
- 1 July 2020
- journal article
- editorial
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (19), 1327-1330
- https://doi.org/10.2217/fon-2020-0311
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Developing combination strategies using PD-1 checkpoint inhibitors to treat cancerSeminars in Immunopathology, 2018
- Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysisBMJ, 2018
- Elements of cancer immunity and the cancer–immune set pointNature, 2017
- Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of CancersPublished by Elsevier ,2016
- Nivolumab in combination with ipilimumab for the treatment of melanomaExpert Review of Anticancer Therapy, 2015
- Classification of current anticancer immunotherapiesOncotarget, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- The Immune Microenvironment of Human Tumors: General Significance and Clinical ImpactCancer Microenvironment, 2012
- Paradoxical roles of the immune system during cancer developmentNature Reviews Cancer, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002